Skip to content

A DERMO-EPIDERMAL AUTOLOGOUS SKIN SUBSTITUTE FOR FURTHER THERAPEUTIC USE

VALIDATION OF A GMP-COMPLIANT BIOPRINTING PROCESS FOR MANUFACTURING A DERMO-EPIDERMAL AUTOLOGOUS SKIN SUBSTITUTE FOR FURTHER THERAPEUTIC USE

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04925323
Acronym
BIOPSKIN
Enrollment
25
Registered
2021-06-14
Start date
2021-01-12
Completion date
2023-10-31
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plastic Surgeries

Brief summary

Innovative technologies in the emerging field of regenerative medicine might allow an improvement in the treatment of deep complex wounds leading to faster and better wound healing. Among them, the bioprinting technology, consisting in printing human cells and biomaterials to create a dermo-epidermal substitute that mimics an alternative of the physiological skin is the most promising alternative. Besides improving skin substitutes properties, bioprinting allows to translate the manufacturing process of tissue-engineered products from manual, operator-dependent processes to a reproducible and automated solution. This paves the way to the manufacturing of therapeutic bioprinted products at the point of care, as close as possible from patients.

Detailed description

In this preclinical in vitro study, the investigators plan to generate GMP-compliant validation batches of bio-printed dermo-epidermal substitutes from 25 healthy volunteer patients' unused surgical tissue removed during plastic surgeries. Volunteer's harvested tissue will allow to extract and then amplify the epidermal keratinocytes and dermal fibroblasts. Successive cultures and bioprinting steps will generate a bio-printed dermo-epidermal substitute in 2 or 3 weeks. A blood test may also be performed on the volunteers to characterize the genetic stability during the different stages of the process.

Interventions

BIOLOGICALBLOOD SAMPLES

BLOOD SAMPLES

BIOLOGICALsurgical tissue samples

unused surgical tissue removed during plastic surgeries

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult adult males or females * Members of a social security scheme. * No contraindications to general anesthesia * Relevant to a plastic or repair surgery indication generating surgical waste.

Exclusion criteria

* Pregnant and/or nursing women * Persons deprived of liberty * Major under guardianship * Persons unable to read the backgrounder.

Design outcomes

Primary

MeasureTime frameDescription
bioprinted dermo epidermal substitute sterility assessment24 MONTHSCulture media from dermo-epidermal bioprinted substitutes were sampled in Bactec culture bottles (Peds Plus Aerobic/F and Plus Anaerobic/F culture vials, containing each 40 mL of medium). The Bactec method (Becton Dickinson, Sparks, MD, USA) uses a computer-controlled incubation/detection system. The media used contained proprietary factors designed to inactivate a wide variety of antibacterial and antifungal agents. Bactec culture bottles were incubated at 37 °C for a total of 10 days, and automated readings were taken every 10 min. Detection of organisms resulted in an audible alarm and automatic recording of time to detection.
Population Doubling Rate of keratinocytes24 MONTHS
Population Doubling Rate of fibroblasts24MONTHS

Countries

France

Contacts

Primary ContactDominique CASANOVA
dominique.casanova@ap-hm.fr04 91 35 38 55
Backup Contactbaptiste BERTRAND
baptiste.bertrand@ap-hm.fr04.91.35.38.55

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026